Under construction – not a live service
Sign in
TerminatedNo phase

The PLATON Network

Reason given: Sponsor Decision

Key facts

Where
Bad Saarow, Berlin, Bochum, Chemnitz, Dortmund, Dresden, Essen, Frankfurt am Main, Goslar, Halle, Hamburg, Herne, Lahr, Landshut, Langen, Leer, Lemgo, Ludwigsburg, München, Münster, Neumünster, Ostfildern, Regensburg, Rheine, Saarbrücken, Singen, Witten, and Wolfsburg, GermanySee the 31 sites

Where in Germany

  • HELIOS Klinikum Bad SaarowBad Saarow, GermanyNo longer taking part
  • Evangelisches Waldkrankenhaus SpandauBerlin, GermanyNo longer taking part
  • MVZ Oskar-Helene-Heim BerlinBerlin, GermanyNo longer taking part
  • Augusta-Kranken-Anstalt BochumBochum, GermanyNo longer taking part
  • Bochum UniBochum, GermanyNo longer taking part
  • Klinikum ChemnitzChemnitz, GermanyNo longer taking part
  • GEFOS - Gesellschaft für onkologische Studien DortmundDortmund, GermanyNo longer taking part
  • Onkozentrum DresdenDresden, GermanyNo longer taking part
  • Ev. Kliniken Essen-Mitte, Klinik für Internistische OnkologieEssen, GermanyNo longer taking part
  • KHNW FrankfurtFrankfurt am Main, GermanyNo longer taking part
  • MVZ Onkologische Kooperation HarzGoslar, GermanyNo longer taking part
  • Universitätsklinikum Halle (Saale)Halle, GermanyNo longer taking part
  • Hamburg Onkologische Schwerpunktpraxis EppendorfHamburg, GermanyNo longer taking part
  • St. Anna Hospital HerneHerne, GermanyNo longer taking part
  • Ortenau Klinikum Lahr-EttenheimLahr, GermanyNo longer taking part
  • ÜBAG - MVZ Dr. Vehling-Kaiser GmbHLandshut, GermanyNo longer taking part
  • Langen, Gemeinschaftspraxis für Hämatologie und OnkologieLangen, GermanyNo longer taking part
  • Studienzentrum UnterEmsLeer, GermanyNo longer taking part
  • Klinikum LippeLemgo, GermanyNo longer taking part
  • Klinikum LudwigsburgLudwigsburg, GermanyNo longer taking part
  • Klinik München-BogenhausenMünchen, GermanyNo longer taking part
  • Münster, Gemeinschaftspraxis für Hämatologie und OnkologieMünster, GermanyNo longer taking part
  • Friedrich-Ebert-Krankenhaus NeumünsterNeumünster, GermanyNo longer taking part
  • Medius Klinik Osterfildern-RuitOstfildern, GermanyNo longer taking part
  • Krankenhaus Barmherzige BrüderRegensburg, GermanyNo longer taking part
  • Klinikum Rheine, Mathias-Spital RheineRheine, GermanyNo longer taking part
  • CaritasKlinikum SaarbrückenSaarbrücken, GermanyNo longer taking part
  • Onkologie BodenseeSingen, GermanyNo longer taking part
  • Marien Hospital WittenWitten, GermanyNo longer taking part
  • Klinikum WolfsburgWolfsburg, GermanyNo longer taking part
  • Onkologisches Zentrum Wolfsburg-Helmstedt MVZ GmbHWolfsburg, GermanyNo longer taking part

Trial details

Who runs it
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Trial code
NCT05489250
Record updated
5 February 2026
Original description
The PLATON Network study is designed to elevate personalized therapy based on genomic tumor profiles in gastrointestinal cancer patients. Hereby, PLATON's study-design focuses on the patient's tumor molecular profiling. Within the network a web application will be developed to link clinical investigators and information on study sites, cancer patients and genetic alteration data, as well as available clinical trials at PLATON's study sites.Read full original descriptionShow less

The Platform for Analyzing Targetable Tumor Mutations Network (Main-study)

The PLATON Network study is designed to elevate personalized therapy based on genomic tumor profiles in gastrointestinal cancer patients. Hereby, PLATON's study-design focuses on the patient's tumor molecular profiling. Within the network a web application will be developed to link clinical investigators and information on study sites, cancer patients and genetic alteration data, as well as available clinical trials at PLATON's study sites.

Inclusion: Histologically confirmed diagnosis of hepatocellular carcinoma or intra- cholangiocarcinoma, extrahepatic cholangiocarcinoma or gallbladder carcinoma or pancreatic ductal adenocarcinoma or esophagogastric adenocarcinoma in the advanced setting (adjuvant or neoadjuvant therapy is allowed if completed 6 months prior to enrolment) and no local curative therapy available; Standard first line therapy is planned, or patient is currently receiving first-line therapy; Available tumor-genomic profile ( ≥50-gene panel assay; approved and assessed by central review), unless central tumor genomic profiling is done within a sub-study; ECOG 0-2; Life expectancy ≥ 6 months.

Exclusion: Age < 18 years; Not able to understand all implications of study participation; No written informed consent.

ClinicalTrials.gov NCT05489250